BioCryst Pharmaceuticals stock tumbled 10% despite revenue increase and raised guidance

From Nasdaq: 2025-02-24 18:15:51

BioCryst Pharmaceuticals (NASDAQ: BCRX) saw a 10% drop in stock price after releasing fourth-quarter and full-year 2024 results, despite a 41% revenue increase to $131.5 million. The company narrowed its net loss to $26.8 million. BioCryst’s main product, Orladeyo, drove sales growth and the company raised its 2025 revenue guidance to $560 million to $575 million. While analysts were impressed with the revenue beat, they were disappointed with the net loss miss. Despite being a one-product company for now, BioCryst is optimistic about future prospects, including expanding approval for Orladeyo to children aged 2 to 11.



Read more at Nasdaq: Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today